Online dose delivery verification in small animal image‐guided radiotherapy

2020 ◽  
Vol 47 (4) ◽  
pp. 1871-1879
Author(s):  
Akbar Anvari ◽  
Arezoo Modiri ◽  
Ravina Pandita ◽  
Javed Mahmood ◽  
Amit Sawant
Keyword(s):  
Small Animal ◽  
Dose Delivery ◽  
Image Guided Radiotherapy ◽  
Image Guided ◽  
Delivery Verification ◽  
Animal Image

Kilovoltage transit and exit dosimetry for a small animal image-guided radiotherapy system using built-in EPID

2018 ◽  
Vol 45 (10) ◽  
pp. 4642-4651 ◽  
Author(s):  
Akbar Anvari ◽  
Yannick Poirier ◽  
Amit Sawant
Keyword(s):  
Small Animal ◽  
Image Guided Radiotherapy ◽  
Image Guided ◽  
Animal Image

scholarly journals Small animal image-guided radiotherapy

2019 ◽  
Vol 92 (1095) ◽  
Author(s):  
Frank Verhaegen ◽  
Pedro Vaz ◽  
Kevin M Prise
Keyword(s):  
Small Animal ◽  
Image Guided Radiotherapy ◽  
Image Guided ◽  
Animal Image

scholarly journals Evaluation of a Novel Liquid Fiducial Marker, BioXmark®, for Small Animal Image-Guided Radiotherapy Applications

Cancers ◽  
2020 ◽  
Vol 12 (5) ◽  
pp. 1276
Author(s):  
Kathryn H. Brown ◽  
Mihaela Ghita ◽  
Giuseppe Schettino ◽  
Kevin M. Prise ◽  
Karl T. Butterworth
Keyword(s):  
Tumour Growth ◽  
Tumour Response ◽  
Small Animal ◽  
Fiducial Marker ◽  
Image Guided Radiotherapy ◽  
Target Delineation ◽  
Image Guided ◽  
Animal Image ◽  
The Impact

BioXmark® (Nanovi A/S, Denmark) is a novel fiducial marker based on a liquid, iodine-based and non-metallic formulation. BioXmark® has been clinically validated and reverse translated to preclinical models to improve cone-beam CT (CBCT) target delineation in small animal image-guided radiotherapy (SAIGRT). However, in phantom image analysis and in vivo evaluation of radiobiological response after the injection of BioXmark® are yet to be reported. In phantom measurements were performed to compare CBCT imaging artefacts with solid fiducials and determine optimum imaging parameters for BioXmark®. In vivo stability of BioXmark® was assessed over a 5-month period, and the impact of BioXmark® on in vivo tumour response from single-fraction and fractionated X-ray exposures was investigated in a subcutaneous syngeneic tumour model. BioXmark® was stable, well tolerated and detectable on CBCT at volumes ≤10 µL. Our data showed imaging artefacts reduced by up to 84% and 89% compared to polymer and gold fiducial markers, respectively. BioXmark® was shown to have no significant impact on tumour growth in control animals, but changes were observed in irradiated animals injected with BioXmark® due to alterations in dose calculations induced by the sharp contrast enhancement. BioXmark® is superior to solid fiducials with reduced imaging artefacts on CBCT. With minimal impact on the tumour growth delay, BioXmark® can be implemented in SAIGRT to improve target delineation and reduce set-up errors.

scholarly journals Small animal image-guided radiotherapy

2017 ◽  
Vol 90 (1069) ◽  
pp. 20160905 ◽  
Author(s):  
Kevin M Prise ◽  
Frank Verhaegen
Keyword(s):  
Small Animal ◽  
Image Guided Radiotherapy ◽  
Image Guided ◽  
Animal Image

PD-0239 PRE-CLINICAL IMPLEMENTATION OF A SMALL ANIMAL IMAGE-GUIDED IRRADIATOR

2012 ◽  
Vol 103 ◽  
pp. S95
Author(s):  
A. Gasparini ◽  
M.C. de Gooijer ◽  
H. te Poele ◽  
F. Stewart ◽  
O. van Tellingen ◽  
...  
Keyword(s):  
Small Animal ◽  
Clinical Implementation ◽  
Image Guided ◽  
Animal Image
Sign in / Sign up

Export Citation Format

Share Document